Interactive Brokers has introduced an Ethereum staking service for Ether (ETH), expanding its cryptocurrency offerings. The new service is supported by technology from ZeroHash, aiming to enhance the brokerage's digital asset capabilities. This move allows investors to stake their ETH directly through Interactive Brokers, potentially earning rewards while holding the asset. It marks a significant step in broadening crypto services within traditional brokerage platforms.
Interactive Brokers' launch of Ethereum staking with ZeroHash support provides context for cryptocurrency market activity. For readers following crypto assets, here is Pluang's market snapshot as of Oct 13, 2026 20:51 WIB: out of 50 major cryptocurrencies priced on Pluang, 7 rose and 42 fell today. Notable movers include BAT (Basic Attention Token) at Rp3.237 with a 1-day change of +21.87% and a typical hold time of 93 days, BAL (Balancer) at Rp16.297 with +11.14%, and ONE (Harmony) at Rp31 with -9.13% and an 83% sell order activity.
Domino's Pizza reported Q3 2026 earnings per share of $4.60, beating analyst expectations of $4.37, while revenue grew modestly by 3.4% to $1.19 billion. Same-store sales growth was minimal at 0.3% in the U.S. and 0.2% internationally, reflecting com...
Citigroup reported Q3 2026 earnings that exceeded analyst expectations, with EPS of $2.85 beating the $2.65 estimate and revenue of $23.8 billion slightly above forecasts. The bank's profit rose 40%, driven by exceptional fixed-income trading, invest...
State Street is set to report its Q3 2026 earnings with forecasts showing a 31.3% increase in earnings and 14% revenue growth, driven by strong net interest income and service fees. Despite record assets under management, higher operating and technol...
Restaurant Technologies, Inc. (RTI) released its 2026 Impact Report highlighting significant progress in sustainability and operational efficiency. In 2025, RTI recycled 393 million pounds of used cooking oil and delivered 719.4 million pounds of fre...
Over 60 companies are actively developing more than 65 medical marijuana therapies targeting conditions like chronic pain, neurological disorders, and cancer symptoms. Key drugs such as ZYN-002 and CardiolRx are in late-stage trials, with others in e...
